ANI Pharmaceuticals, Inc.
ANIP
$95.20
-$0.15-0.16%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 53.12% | 43.43% | 44.75% | 12.52% | 18.44% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 53.12% | 43.43% | 44.75% | 12.52% | 18.44% |
| Cost of Revenue | 29.32% | 48.58% | 50.28% | 31.13% | 36.45% |
| Gross Profit | 70.22% | 40.57% | 40.98% | 1.83% | 8.19% |
| SG&A Expenses | 65.79% | 57.49% | 56.36% | 67.29% | 27.25% |
| Depreciation & Amortization | 58.41% | 55.87% | 48.74% | 3.56% | 0.05% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 52.08% | 48.82% | 53.77% | 36.75% | 25.12% |
| Operating Income | 68.02% | -0.35% | -82.45% | -170.77% | -32.82% |
| Income Before Tax | 560.21% | -21.11% | -1,553.22% | -373.63% | -143.57% |
| Income Tax Expenses | -- | -39.59% | -1,575.96% | -566.71% | -- |
| Earnings from Continuing Operations | 473.81% | -13.87% | -989.70% | -343.12% | -136.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 473.81% | -13.87% | -989.70% | -343.12% | -136.62% |
| EBIT | 68.02% | -0.35% | -82.45% | -170.77% | -32.82% |
| EBITDA | 62.07% | 27.41% | 0.94% | -84.14% | -15.66% |
| EPS Basic | 364.85% | -16.50% | -1,592.66% | -376.67% | -146.97% |
| Normalized Basic EPS | 160.75% | -9.21% | -295.54% | -271.26% | -37.60% |
| EPS Diluted | 358.14% | -16.91% | -1,604.93% | -380.73% | -148.28% |
| Normalized Diluted EPS | 154.69% | -9.69% | -297.80% | -273.42% | -37.00% |
| Average Basic Shares Outstanding | 2.66% | 2.66% | 2.33% | 2.76% | 9.23% |
| Average Diluted Shares Outstanding | 5.11% | 3.21% | 1.18% | 1.46% | 8.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 1.27% | 0.16% | -1.11% | -1.41% | -3.73% |